The device utilises procedural CT images and temperature data to real-time display of the ablation zone. Credit: PeopleImages.com – Yuri A / Shutterstock.

HEPTA Medical has announced a €5.7m ($6.30m) initial close of its Series A funding round, led by BPI France, to further develop its microwave ablation platform for lung cancer treatment.

The investment will facilitate the US regulatory approval process and the commencement of clinical trials for the platform.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

HEPTA’s flexible microwave ablation platform aims to revolutionise early-stage lung cancer management with a non-invasive approach.

The microwave ablation probe is compatible with any lung navigation system and features a unique patented tissue temperature sensor for real-time, in-situ monitoring of ablation zone growth during endobronchial ablation procedures.

HEPTA Medical CEO Dr Thomas Bancel said: “We are grateful for our new investors and excited to bring microwave ablation therapy to new heights. In August, we obtained our first proprietary patent, completing our three patent families under licence.

See Also:

“We have multiple upcoming milestones, including the release of early preclinical trial results conducted in collaboration with world-renowned centres, which we’ll publish at the CIRSE conference in September.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The device features AI-powered predictive software and uses procedural CT images and temperature data to provide clinicians with a real-time display of the ablation zone, enhancing the precision and safety of the treatment.

BPI France Life Sciences Investments deputy chief Philippe Boucheron said: “HEPTA’s unique approach to thermal ablation therapy, combined with their dedicated team and cutting-edge technology, positions them at the forefront of transforming lung cancer care.

“We are confident that HEPTA Medical will achieve significant milestones in the near future and are excited to support their continued growth and success.”